secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alzamend Neuro, Inc. (ALZN)
CIK:        0001677077
Form:       8-K
Filed at:   2024-10-15T23:59:59+00:00
Accession:  0001214659-24-017549
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alzamend Neuro regains Nasdaq compliance; avoids delisting
----------------------------------------------------------

- Received written notice from Nasdaq Hearings Panel on Oct 14, 2024 that it has regained compliance with minimum stockholders' equity rule ($2.5M required).
- Had been notified of delisting in March 2024, appealed to Panel, granted extension until Sept 23, 2024.
- Entered $25M Series A Convertible Preferred purchase agreement; $8M already funded, additional $2M due in 30 days, $1M monthly through Jan 2026.
- CEO Stephan Jackman states strategic plan executed; company intends to initiate five phase II AL001 trials in 2025 with Massachusetts General Hospital.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1677077/000121465924017549/0001214659-24-017549-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1677077/000121465924017549/o10142408k.htm
  HTML page:      https://secwatch.observer/filing/0001214659-24-017549

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer